Jain Global’s Acadia Pharmaceuticals ACAD Stock Holding History

Jain Global’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,051	Closed	-$300K	–	1194
2025 Q3	$300K	Sell	14,051 -8,105	-37%	-$192K	﹤0.01%	821
2025 Q2	$478K	Buy	22,156 +7,797	+54%	+$145K	﹤0.01%	800
2025 Q1	$239K	Sell	14,359 -57,853	-80%	-$1.05M	﹤0.01%	770
2024 Q4	$1.33M	Buy	+72,212	New	+$1.17M	0.04%	283

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Jain Global's ACAD Position: Q4 2025 in Review

Jain Global sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 14,051 shares — an estimated $300K sold.

Jain Global first reported a position in ACAD in Q4 2024 and held it in 4 quarters. The position peaked at $1.33M in Q4 2024. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

Jain Global reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Jain Global sold 14,051 Acadia Pharmaceuticals shares in Q4 2025, an estimated $300K.
Jain Global first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Jain Global's Acadia Pharmaceuticals position peaked at $1.33M in Q4 2024.
336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Jain Global's 13F filing for Q4 2025, filed 17 Feb 2026.